Anti-Aging · Reference
FOXO4-DRI for Men: What the Testosterone and Leydig Cell Research Actually Shows
This page covers what FOXO4-DRI is, what research has and has not looked at in men, the considerations that matter for men, and how Pepti supplies it. For the general evidence, benefit by benefit, see FOXO4-DRI benefits; for the product reference, what is FOXO4-DRI.
Treatments mentioned
The research most often quoted about FOXO4-DRI for men is two mouse studies on the aging male reproductive system: a 2020 paper in Aging that linked FOXO4 in human Leydig cells to lower testosterone synthesis and reported improved testosterone secretion in aged mice after FOXO4-DRI, and a 2024 paper in Experimental Gerontology that reported improved sperm quality in naturally aged mice. No study has given FOXO4-DRI to a man. The only human part of that work was observational analysis of testicular tissue, and there are no human trials of FOXO4-DRI for any purpose. It is not a hormone and not a testosterone treatment, and compounded FOXO4-DRI is not FDA approved.
This page covers what FOXO4-DRI is, what research has and has not looked at in men, the considerations that matter for men, and how Pepti supplies it. For the general evidence, benefit by benefit, see FOXO4-DRI benefits; for the product reference, what is FOXO4-DRI.
FOXO4-DRI for Men
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has FOXO4-DRI been studied in men? | No. No man has been treated in a published study | None |
| Does it raise testosterone? | In aged mice, clearing senescent Leydig cells was associated with improved testosterone secretion (Aging, 2020) | Mouse only |
| Is FOXO4 found in human testes? | Yes. The 2020 paper reported FOXO4 in human Leydig cells, with nuclear localisation in elderly men correlating with lower testosterone synthesis | Human observational tissue analysis, not treatment |
| Does it affect sperm or fertility? | Improved sperm quality and spermatogenesis in naturally aged mice (Experimental Gerontology, 2024) | Mouse only |
| Does it reverse aging in men? | Not studied in people. The 2017 Cell paper reported restored fitness, fur density and kidney function in aged mice | Mouse only |
| Is it a hormone or a TRT alternative? | No. It acts on senescent cells, not on any hormone receptor | Mechanism |
The honest summary: an interesting male-specific mouse story, one observational look at human tissue, and no treatment data in men.
FOXO4-DRI for Men
What FOXO4-DRI is, in one paragraph
FOXO4-DRI is a designed peptide described in a 2017 paper in Cell from the laboratory of Peter de Keizer in Rotterdam. Senescent cells are cells that have permanently stopped dividing but have not died, and they secrete inflammatory signals into the tissue around them. In those cells a transcription factor called FOXO4 holds p53 in the nucleus and keeps it from triggering the cell's own death programme. FOXO4-DRI copies a stretch of FOXO4 and acts as a decoy; in mouse and cell studies, the senescent cell then undergoes apoptosis while dividing cells are described as unaffected. It is built from D-amino acids in reverse order, which is what "DRI" means, so it resists breakdown, and it carries a short cell-penetrating tag. It does not act on the androgen receptor, the pituitary or growth hormone.
FOXO4-DRI for Men
What research has looked at in men
The 2020 Leydig cell study
Leydig cells are the cells in the testes that make testosterone. A group in China reported in Aging in 2020 that FOXO4 is expressed in human Leydig cells and that its nuclear localisation in tissue from elderly men correlated with lower testosterone synthesis. In aged mice, FOXO4-DRI cleared senescent Leydig cells and was associated with improved testosterone secretion.
What it shows. That FOXO4 is present where testosterone is made, that in older human tissue its location tracks with lower synthesis, and that in old mice removing senescent Leydig cells went with better testosterone output.
What it does not show. The human part was observational tissue analysis. No man received FOXO4-DRI, no human testosterone level was measured after treatment, and a correlation in tissue does not show that changing FOXO4 changes testosterone in a living person.
The 2024 sperm quality study
The same group reported in Experimental Gerontology in 2024 that, in naturally aged mice, FOXO4-DRI was associated with improved sperm quality and spermatogenesis, with reduced output of the inflammatory secretions of senescent Leydig cells and a knock-on effect on neighbouring cells in co-culture.
What it shows. A consistent second mouse finding in the same tissue.
What it does not show. Anything about human fertility. It is not a fertility treatment, and men who are trying to conceive should tell their physician before starting any experimental compound; see do peptides affect fertility.
The findings that apply to both sexes
The 2017 Cell paper, the source of most claims made for FOXO4-DRI, treated fast-aging and naturally old mice and reported restored running-wheel activity, fur density and kidney function after a short course of intermittent intraperitoneal injection. It also reported that FOXO4-DRI neutralised chemotherapy-induced toxicity in mice. Later mouse work described milder lung fibrosis in a bleomycin model (2023) and reduced aortic aging markers (2026), and two studies used human cells in a dish: chondrocytes (2021) and keloid fibroblasts (2025). None of it is described as reporting separate results by sex, and none is a human treatment result. "Fur density" in mice is not a hair-loss study in men.
FOXO4-DRI for Men
What changes for men
Low testosterone has a proper workup
If the reason you are looking at FOXO4-DRI is low energy, low libido or a worry about testosterone, that is a bloodwork and physician conversation, not a reason to start a senolytic. FOXO4-DRI is not a testosterone treatment, and the only testosterone data is in mice. How peptides differ from testosterone therapy is covered in peptides vs TRT and steroids, and the wider options for older men are in peptides for men over 40.
Cancer history
Senescence is one of the body's defences against cancer: a damaged cell is parked rather than allowed to divide. FOXO4-DRI acts on p53, the central tumour-suppressor protein, and nobody has studied what that means over time in humans. A personal or family history of any cancer, including prostate cancer, goes on the intake in full and is a reason to discuss FOXO4-DRI carefully before anything is prescribed. More is in can peptides cause cancer.
Lungs and heart
A 2023 study in Circulation reported that eliminating senescent cells in the pulmonary vessels of mice, using senolytic interventions, worsened pulmonary hypertension. That is a finding about senolytics as a class in mice, and it has not been shown in people, but anyone with pulmonary hypertension or significant lung disease should raise it at intake.
Tested sport
FOXO4-DRI is not named on the WADA Prohibited List, but the S0 class prohibits at all times any pharmacological substance with no current approval for human therapeutic use, and that wording can reach it. Men who compete in a tested sport should read is FOXO4-DRI banned in sports before starting.
FOXO4-DRI for Men
What the evidence does not establish
- That FOXO4-DRI raises testosterone, improves sperm or changes fertility in men. Those are mouse findings.
- That it clears senescent cells in humans at all. Every senolytic observation is from mice or cultured cells.
- Any effect on energy, muscle, libido, hair, appearance or lifespan in men.
- A human dose, schedule or route. The mouse work used short courses of intraperitoneal injection.
- Human safety, short-term or long-term. No adverse-event series, pharmacokinetic study or long-term follow-up exists.
- What happens with repeated courses.
FOXO4-DRI for Men
Side effects and considerations
Nothing in the live research suggests the picture differs between men and women. The safety record is a mouse record.
| What is reported or relevant | What to do |
|---|---|
| Injection-site redness, mild soreness, occasional bruising | Rotate sites between abdomen and thigh |
| Immune reactions to the peptide's unusual chemistry | A theoretical concern, not studied in people; report a rash or hives away from the site |
| Cancer history, personal or family | Put it on the intake; FOXO4-DRI acts on p53 |
| Pulmonary hypertension or lung disease | Raise it at intake because of the 2023 mouse finding |
| Facial or throat swelling, widespread rash, difficulty breathing | Call 911 first, then tell your physician |
There is no established interaction list, because the trials that would produce one have not been run. List every medication you take, including anything for blood pressure, prostate or erectile function.
FOXO4-DRI for Men
Where FOXO4-DRI stands with the FDA
As of the FDA's 503A nominated-substances document updated 14 May 2026, FOXO4-DRI does not appear in Category 1, Category 2 or Category 3. It is not on the FDA's page of bulk substances that may present significant safety risks, not on the 503A bulks list at 21 CFR 216.23, and it was not on the agenda of the Pharmacy Compounding Advisory Committee's July 2026 meeting or the meeting announced for early 2027. The FDA has not evaluated it either way. Compounded FOXO4-DRI is not FDA approved. More on the legal side is in do you need a prescription for FOXO4-DRI.
FOXO4-DRI for Men
How Pepti supplies FOXO4-DRI
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| FOXO4-DRI | 5 mL multi-dose vial, 2 mg/mL (10 mg FOXO4-DRI) | 0.25 mL (25 units) subcutaneously once daily Monday through Friday; 0.5 mg per dose (math only), 20 doses, about 4 weeks | $229/mo |
Refills run every 28 days, one vial per fill, and prescribers generally treat FOXO4-DRI as an intermittent course, so whether a further vial follows is reviewed each time. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The unit chart is in FOXO4-DRI dosage.
The price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive as solutions ready to use, with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
Other anti-aging options men ask about
| Product | What it is aimed at | Human data | Price |
|---|---|---|---|
| FOXO4-DRI | Removing senescent cells | None | $229/mo |
| NAD+ Injection | Cellular energy metabolism and DNA repair | Precursor trials in people; none of the injection | $249/mo |
| Epithalon | Telomere and pineal biology | Older Russian work | $249/mo |
| MOTS-c | Mitochondrial metabolic signalling | Observational only | $259/mo |
| SS-31 | The inner mitochondrial membrane | Randomised trials of elamipretide in rare disease and heart failure | $249/mo |
The comparisons are in NAD+ vs FOXO4-DRI, Epithalon vs FOXO4-DRI, FOXO4-DRI vs MOTS-c and SS-31 vs FOXO4-DRI.
FOXO4-DRI for Men
Where to get FOXO4-DRI prescribed
FOXO4-DRI cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications, any cancer or lung history, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and side effects.
Pepti prescribes in most US states, not currently in Oklahoma, and the assessment confirms availability for your state. Step by step: how to get FOXO4-DRI prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Baar MP, Brandt RMC, Putavet DA et al.. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell (2017) · PMID 28340339
- Bourgeois B, Spreitzer E, Platero-Rochart D et al.. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications (2025) · PMID 40593617
- Zhang C, Xie Y, Chen H et al.. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice · Aging (Albany NY) (2020) · PMID 31959736
- Huang Y, He Y, Makarcyzk MJ et al.. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology (2021) · PMID 33996787
- Liu Y, Hou Q, Wang R et al.. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice · Naunyn-Schmiedeberg's Archives of Pharmacology (2023) · PMID 37074394
- Li Y, Zhang C, Cheng H et al.. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells · Experimental Gerontology (2024) · PMID 39025385
- Hu Z, Li F, Hu C et al.. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway · Frontiers in Bioengineering and Biotechnology (2026) · PMID 41625068
- Kong YX, Li ZS, Liu YB et al.. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation · Communications Biology (2025) · PMID 39994346
- Born E, Lipskaia L, Breau M et al.. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation (2023) · PMID 36515093
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
FOXO4-DRI for Men, answered.
No study has treated men with it. The male-specific research is two mouse studies on aged Leydig cells, testosterone and sperm quality, plus an observational look at human testicular tissue. Any benefit for men is described in mice, not established in people.
Not in any human study, because there are none. A 2020 mouse study in Aging reported that clearing senescent Leydig cells with FOXO4-DRI was associated with improved testosterone secretion in aged mice. FOXO4-DRI is not a hormone or a hormone-releasing peptide.
No. It does not act on the androgen receptor or the pituitary and has no human testosterone data. Low testosterone needs its own workup with your physician.
A 2024 mouse study reported improved sperm quality and spermatogenesis in naturally aged mice. There is no human fertility data. If you are trying to conceive, tell your physician before starting.
Not studied. The 2017 Cell paper reported restored fur density in aged mice, which is not a hair-loss study in men.
The same as for anyone: mostly injection-site redness, soreness or bruising, with no published human safety data. A history of cancer, including prostate cancer, or of lung disease should be discussed first.
That is a conversation to have before anything is prescribed. FOXO4-DRI acts on p53, the central tumour-suppressor protein, and its long-term effects in people have not been studied. Put the full history on your intake.
Age alone is not described as an exclusion. Older men are more likely to have the cancer, heart and lung history that needs discussing first, so the intake asks about all of it.
No human study has measured that. The mouse studies used short courses and measured over days to weeks in animals that age in two years. See how long does FOXO4-DRI take to work.
At Pepti, $229 a month all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.